<?xml version='1.0' encoding='utf-8'?>
<document id="25609219"><sentence text="Physiologically based pharmacokinetic modeling for sequential metabolism: effect of CYP2C19 genetic polymorphism on clopidogrel and clopidogrel active metabolite pharmacokinetics."><entity charOffset="116-127" id="DDI-PubMed.25609219.s1.e0" text="clopidogrel" /><entity charOffset="132-143" id="DDI-PubMed.25609219.s1.e1" text="clopidogrel" /><pair ddi="false" e1="DDI-PubMed.25609219.s1.e0" e2="DDI-PubMed.25609219.s1.e0" /><pair ddi="false" e1="DDI-PubMed.25609219.s1.e0" e2="DDI-PubMed.25609219.s1.e1" /></sentence><sentence text="Clopidogrel is a prodrug that needs to be converted to its active metabolite (clopi-H4) in two sequential cytochrome P450 (P450)-dependent steps"><entity charOffset="0-11" id="DDI-PubMed.25609219.s2.e0" text="Clopidogrel" /></sentence><sentence text=" In the present study, a dynamic physiologically based pharmacokinetic (PBPK) model was developed in Simcyp for clopidogrel and clopi-H4 using a specific sequential metabolite module in four populations with phenotypically different CYP2C19 activity (poor, intermediate, extensive, and ultrarapid metabolizers) receiving a loading dose of 300 mg followed by a maintenance dose of 75 mg"><entity charOffset="112-123" id="DDI-PubMed.25609219.s3.e0" text="clopidogrel" /></sentence><sentence text=" This model was validated using several approaches" /><sentence text=" First, a comparison of predicted-to-observed area under the curve (AUC)0-24 obtained from a randomized crossover study conducted in four balanced CYP2C19-phenotype metabolizer groups was performed using a visual predictive check method" /><sentence text=" Second, the interindividual and intertrial variability (on the basis of AUC0-24 comparisons) between the predicted trials and the observed trial of individuals, for each phenotypic group, were compared" /><sentence text=" Finally, a further validation, on the basis of drug-drug-interaction prediction, was performed by comparing observed values of clopidogrel and clopi-H4 with or without dronedarone (moderate CYP3A4 inhibitor) coadministration using a previously developed and validated physiologically based PBPK dronedarone model"><entity charOffset="128-139" id="DDI-PubMed.25609219.s7.e0" text="clopidogrel" /><entity charOffset="169-180" id="DDI-PubMed.25609219.s7.e1" text="dronedarone" /><entity charOffset="296-307" id="DDI-PubMed.25609219.s7.e2" text="dronedarone" /><pair ddi="false" e1="DDI-PubMed.25609219.s7.e0" e2="DDI-PubMed.25609219.s7.e0" /><pair ddi="false" e1="DDI-PubMed.25609219.s7.e0" e2="DDI-PubMed.25609219.s7.e1" /><pair ddi="false" e1="DDI-PubMed.25609219.s7.e0" e2="DDI-PubMed.25609219.s7.e2" /><pair ddi="false" e1="DDI-PubMed.25609219.s7.e1" e2="DDI-PubMed.25609219.s7.e1" /><pair ddi="false" e1="DDI-PubMed.25609219.s7.e1" e2="DDI-PubMed.25609219.s7.e2" /></sentence><sentence text=" The PBPK model was well validated for both clopidogrel and its active metabolite clopi-H4, in each CYP2C19-phenotypic group, whatever the treatment period (300-mg loading dose and 75-mg last maintenance dose)"><entity charOffset="44-55" id="DDI-PubMed.25609219.s8.e0" text="clopidogrel" /></sentence><sentence text=" This is the first study proposing a full dynamic PBPK model able to accurately predict simultaneously the pharmacokinetics of the parent drug and of its primary and secondary metabolites in populations with genetically different activity for a metabolizing enzyme" /><sentence text=" " /></document>